425: CoreWeave Files SEC Form 425 Regarding Proposed Acquisition of Core Scientific

CoreWeave, Inc. filed a Form 425 communication on LinkedIn regarding its proposed acquisition of Core Scientific, Inc., directing stakeholders to comprehensive SEC filings for detailed transaction information.

Summary

• CoreWeave, Inc. posted a communication on its LinkedIn account on July 8, 2025, concerning its proposed acquisition of Core Scientific, Inc.
• The communication serves as a Form 425 filing with the U.S. Securities and Exchange Commission (SEC).
• CoreWeave and Core Scientific will file relevant materials with the SEC, including a registration statement on Form S-4 by CoreWeave, which will incorporate a proxy statement of Core Scientific and a prospectus of CoreWeave.
• A definitive proxy statement/prospectus will be mailed to stockholders of Core Scientific.
• Investors and security holders are urged to read the registration statement, proxy statement/prospectus, and other relevant documents filed with the SEC carefully and in their entirety when they become available.
• Information about the directors and executive officers of both Core Scientific and CoreWeave is available in their respective prior SEC filings, including proxy statements, Form 10-K, Form 8-K, and Prospectus documents.
• The communication explicitly states it is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor a solicitation of any vote or approval.

Sentiment

Score: 6

Explanation: The document is a procedural SEC filing announcing a proposed acquisition and detailing the associated risks and where to find more information. While the acquisition itself is a significant corporate event, the document's tone is neutral and legally cautious, focusing on disclosure and disclaimers rather than strategic benefits or financial performance.

Risks

• The completion of the proposed transaction on anticipated terms, or at all, and the timing of completion, including obtaining required regulatory approvals and Core Scientific stockholder approval.
• Anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies for the combined company.
• The possibility that any anticipated benefits of the proposed transaction will not be realized or will not be realized within the expected time period.
• The ability of CoreWeave and Core Scientific to integrate their businesses successfully and to achieve anticipated synergies and value creation.
• Potential litigation relating to the proposed transaction that could be instituted against CoreWeave, Core Scientific, or their respective directors and officers.
• Disruptions from the proposed transaction harming CoreWeave's or Core Scientific's business, including current plans and operations, and diversion of management's time and attention.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction.
• Rating agency actions and CoreWeave's and Core Scientific's ability to access shortand long-term debt markets on a timely and affordable basis.
• Legislative, regulatory, and economic developments and actions targeting public companies in the artificial intelligence, power, data center, and crypto mining industries, and changes in local, national, or international laws, regulations, and policies.
• Potential business uncertainty, including the outcome of commercial negotiations and changes to existing business relationships during the pendency of the proposed transaction.
• Certain restrictions during the pendency of the proposed transaction that may impact Core Scientific's ability to pursue certain business opportunities or strategic transactions.
• Acts of terrorism or outbreak of war, hostilities, civil unrest, attacks against CoreWeave or Core Scientific, and other political or security disturbances.
• Dilution caused by CoreWeave's issuance of additional shares of its securities in connection with the proposed transaction.
• The possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events.
• The impacts of pandemics or other public health crises, including the effects of government responses on people and economies.
• Global or regional changes in the supply and demand for power and other market or economic conditions that impact demand and pricing.
• Changes in technical or operating conditions, including unforeseen technical difficulties.
• Development delays at CoreWeave and/or Core Scientific data center sites, including any delays in the conversion of such sites from crypto mining facilities to high-performance computing sites.

Future Outlook

Forward-looking statements address future business and financial events, conditions, expectations, plans, or ambitions, including the consummation of the proposed transaction and its anticipated benefits. These statements are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed. Neither CoreWeave nor Core Scientific assumes any obligation to publicly provide revisions or updates to any forward-looking statements, except as required by law.

Industry Context

The proposed acquisition involves companies operating in the artificial intelligence, power, data center, and crypto mining industries. A key strategic element mentioned as a risk factor is the potential for development delays at data center sites, including the conversion of crypto mining facilities to high-performance computing sites, indicating a strategic shift or expansion within the data center sector towards AI/HPC capabilities.

Stakeholder Impact

• Shareholders of Core Scientific will be required to make voting or investment decisions regarding the proposed transaction and will receive a proxy statement/prospectus.
• Shareholders of CoreWeave may experience dilution due to the issuance of additional shares in connection with the transaction.
• Employees of both companies may be impacted by business integration efforts and potential diversions of management's time and attention.
• Customers and suppliers may experience changes to business relationships or potential adverse reactions resulting from the announcement or completion of the proposed transaction.

Next Steps

• CoreWeave and Core Scientific will file a registration statement on Form S-4, including a proxy statement/prospectus, with the SEC.
• A definitive proxy statement/prospectus will be mailed to stockholders of Core Scientific.
• Core Scientific stockholders will need to approve the proposed transaction.
• Regulatory approvals that may be required for the transaction must be obtained.
• CoreWeave and Core Scientific will work to integrate their businesses successfully to achieve anticipated synergies and value creation.

Key Dates

Keywords

CoreWeave, Core Scientific, Acquisition, Merger, SEC Filing, Form 425, Form S-4, Proxy Statement, Prospectus, Data Center, High-Performance Computing, Crypto Mining, Corporate Transaction